Stock Forecast

  Pliant Therapeutics, Inc. ( PLRX) Stock. Should you Buy or Sell?    $ 22.23

1.86 (7.72 %)

Pliant Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol PLRX
Price $22.23
Beta 1.626
Volume Avg. $2.09 M
Market Cap $1.08 B
52 Week Range $3.965 - $23.0

Pliant Therapeutics, Inc. opened the day at $22.23 which is +'7.72 % on yesterday's close. Pliant Therapeutics, Inc. has a 52 week high of $23.0 and 52 week low of $3.965, which is a difference of $19.035. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.08 B and total net profit is $7572000 which means the company is trading at 142.92 times profit to market capitalization. Theoretically, if you were to buy Pliant Therapeutics, Inc. for $1.08 B, it would take 15 years to get your money back. Pliant Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Pliant Therapeutics, Inc. Stock Forecast - Is Pliant Therapeutics, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreSell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -7.362
Dividend Yiel 0.000
Net Profit Margin -11.092

Valuing Pliant Therapeutics, Inc.

Price Book Value Ratio 5.441 Price To Book Ratio 5.441
Price To Sales Ratio 81.662 Price Earnings Ratio -7.362

How liquid is Pliant Therapeutics, Inc.

Current Ratio 7.694
Quick Ratio 7.493


Debt Ratio 0.199 Debt Equity Ratio 0.249
Long Term Debt To Capitalization 0.088 Total Debt To Capitalization 0.099

Latest news about Pliant Therapeutics, Inc.

Has Pliant Therapeutics (PLRX) Outpaced Other Medical Stocks This Year?

Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.

Date : 06/09/2022

Pliant Therapeutics, Inc. (PLRX) Upgraded to Buy: What Does It Mean for the Stock?

Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Date : 05/09/2022

Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

Date : 02/09/2022

How Much Upside is Left in Pliant Therapeutics, Inc. (PLRX)? Wall Street Analysts Think 127%

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Date : 01/09/2022

Pliant Therapeutics to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant's senior management will participate in the following September investor conferences:

Date : 30/08/2022

About Pliant Therapeutics, Inc.

CEO : Prof. Bernard Coulie M.B.A., Ph.D., M.D., MBA
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : NASDAQ Global Select

Description :

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

My Newsletter

Sign Up For Updates & Newsletters